Jefferson Oncology Group Established to Enhance Clinical Trial Development

Publication
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

The Jefferson Cancer Network of Thomas Jefferson University’s Kimmel Cancer Center recently established a cooperative program known as the Jefferson Oncology Group among its members. The purpose of this new cooperative program is to

The Jefferson Cancer Network of Thomas Jefferson University’s Kimmel Cancer Center recently established a cooperative program known as the Jefferson Oncology Group among its members. The purpose of this new cooperative program is to enhance clinical and translational cancer research and, in particular, the development of clinical trials. In establishing this program, the Jefferson Cancer Network "created an infrastructure that will expand both clinical and translational research."

"We want the best opportunity to create a mechanism in which clinical trials can be conducted as a true partnership among network members," said Walter Curran, Jr., MD, professor and chair of radiation oncology and clinical director of the Kimmel Cancer Center and the Jefferson Oncology Group.

Linking Clinical and Translational Research

Several multi-institution, national cooperative groups currently exist to conduct clinical trials, and "most people feel that research must be national to be conclusive." "We think we now have the capability to conduct conclusive trials on our own," Dr. Curran said. "The research centers at Kimmel Cancer Center and at Lankanau Medical Research Center can link the 20,000 patients diagnosed with cancer in our network with the basic science at these sites for translational research. We also have the appropriate infrastructure and technology in place to compete for funding for clinical trials from the National Cancer Institute and the American Cancer Society."

"Previously, each Jefferson Cancer Network member had to independently participate in a trial. Now, we can go collectively with an idea, say for treating metastatic breast cancer, and obtain support to conduct trials collectively," explained Dr. Curran. In addition, the establishment of the Jefferson Oncology Group will enhance communication among member institutions and community physicians. Trials will be overseen by a single, centralized institutional review board.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content